Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory condi...
Inyx reported revenue of $495.65 million for fiscal year 2005, up 3057.2% from fiscal year 2004, and net income of -$31.01 million. In Q3 2006 (the quarter ended September 30, 2006) revenue was $18.01 million, up 39.5% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2005.
No profile data available.